Recent data on the natural history of Alzheimer's disease: Results from the REAL.FR study

Journal of Nutrition, Health and Aging

Volumn 9, Issue 2, 2005, Pages 86-93

  Cortes, Frederic ^a,b,c   Gillette Guyonnet, S ^a,b   Nourhashemi, F ^a,b   Andrieu, S ^b   Cantet, C ^a,b   Vellas, B ^a,b  

^a IRIT   (France)

^b INSERM   (France)

^c Serv Univ Psychiat l'Enfant l'A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN PROTECTION; CAREGIVER; COGNITION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL ASPECT; TREATMENT OUTCOME;

EID: 16444374923     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000;19:1401-1409.
2. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-883.
3. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al.; "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
4. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicenter open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
5. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al., on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-640.
6. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276.
7. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-I Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomised controlled trial. BMJ 2000;321:1445-1449.
8. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: APA, 1994.
11. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, Cantet C, Micas M, Ousset PJ, et al.; REAL.FR group. The REAL.FR research program on Alzheimer's disease and its management: methods and preliminary results. J Nutr Health Aging 2003;7:91-96.
12. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
14. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
15. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
17. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
18. Reisberg B, Ferns SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
19. Vellas B, Guigoz Y, Garry PJ, Nourhashemi F, Bennahunr D, Lauque S, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999;2:116-122.
20. Zarit SH, Reever K, Bach-Peterson J. Relatives of the impaired elderly: Correlates of feelings of burden. Gerontologist 1980;20:649-655.
21. Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457-2465.
22. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
23. Green CR, Mohs RC, Schmeidler J, Aryan M, Davis KL. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc 1993;41:654-661.
24. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
25. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff L; Donepezil Study Group. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
26. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A-L, Zhang R, Haglund A, Subbiah P and the Donepezil Nordic Study Group. A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001:57:489-495.
27. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.
28. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
29. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 1996;44:265-272.
30. Tsuji I, Whalen S, Finucane TE. Predictors of nursing home placement in community-based long-term care. J Am Geriatr Soc 1995;4:761-766.
31. Coen RF, Swanwick GR, O'Boyle CA, Coakley C. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:331-336.
32. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:248-256.
33. Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993:33:714-720.